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The Interactive Effects of Antisocial Personality Disorder and
Court-Mandated Status on Substance Abuse Treatment Dropout
Stacey B. Daughters, Ph.D., Brooke A. Stipelman, Marsha N. Sargeant, Randi Schuster,
Marina A. Bornovalova, and C.W. Lejuez, Ph.D.
Center for Addictions, Personality, and Emotion Research, University of Maryland

Abstract
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The present study sought to examine the interactive effects of court-mandated (CM) treatment and
antisocial personality disorder (ASPD) on treatment dropout among 236 inner-city male substance
users receiving residential substance abuse treatment through a pretrial release to treatment
program. Of the 236 participants, 39.4% (n = 93) met criteria for ASPD and 72.5 % (n = 171)
were mandated to treatment by the court system. Results indicated a significant interaction
between ASPD and CM status, such that ASPD patients voluntarily receiving treatment were
significantly more likely to drop out of treatment than each of the other groups. Subsequent
discrete-time survival analyses to predict days until dropout using Cox proportional hazards
regression indicated similar findings, with ASPD patients voluntarily receiving treatment
completing fewer days of treatment than each of the other groups. These findings suggest the
effectiveness of the court system in retaining ASPD patients, as well as the role of ASPD in
predicting treatment dropout for individuals who are voluntarily in treatment. Implications are
discussed including the potential value of early implementation of specialized interventions aimed
at improving adherence for ASPD patients who are receiving treatment voluntarily.

Keywords
Substance Abuse Treatment; Antisocial Personality Disorder; Court Mandated; Treatment
Dropout

1. Introduction
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Antisocial Personality Disorder (ASPD) is defined by the DSM-IV as a pervasive pattern of
disregard for and violation of the rights of others, and is characterized by chronic deviant
behavior, deceitfulness, and a lack of conscience (APA, 1994). Although ASPD is present in
only about 3-4% of the general population (Kessler et al., 1994), it is highly pervasive
among individuals with a substance use disorder. Approximately 90% of individuals
diagnosed with ASPD are concomitant substance abusers (Forrest, 1991), and rates of ASPD
are upwards of 40-50% in drug treatment samples (Brooner, King, Kidorf, Schmidt, &
Bigelow, 1997; Messina, Wish, & Nemes, 1999). This dual diagnosis is especially
problematic due to its association with a number of negative outcomes such as aggressive
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and violent behavior (Brooner, Schmidt, Felch, & Bigelow, 1992; Cottler, Price, Compton,
& Mager, 1995), serious criminal activity (e.g. use of a weapon, felony arrests; Abrams,
1989; Brooner et al., 1992; Cottler et al., 1995), elevated risk of contracting and transmitting
HIV (Brooner, Greenfield, Schmidt, & Bigelow, 1993; Compton, Cottler, Shillington, &
Price, 1995) and illicit drug use (Compton, Cottler, Jacobs, Ben-Abdallah, & Spitznagel,
2003; King, Kidorf, Stoller, Carter & Brooner, 2001).
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Recent research has begun to focus on the ability of traditional substance use treatment
settings to retain patients with both ASPD and substance dependence, as treatment length is
one of the most consistent predictors of successful substance use outcomes (Gossop,
Marsden, Stewart, & Treacy, 2002; Martin et al., 2003; Simpson, Joe, & Brown, 1997).
There have been a number of studies suggesting that substance users with comorbid ASPD
are at an increased risk for treatment dropout and subsequent return to drug use and criminal
behavior (e.g. Alterman, Rutherford, Cacciola, McKay, & Boardman, 1998; Cacciola,
Rutherford, Alterman, McKay, & Snider, 1996; Carroll, Ball, & Rounsaville, 1993;
Greenberg, Otero, & Villanueva, 1994; Kokkevi, Stefanis, Anastasopoulou, & Kostogianni,
1998; Leal, Ziedonis, & Kosten, 1994). In particular, some have suggested that substance
users with ASPD lack the intrinsic motivation necessary to remain in treatment long enough
to achieve the full benefits (e.g., Condelli & Hubbard, 1994). However, these finding have
not been consistent, with a handful of other studies reporting either success in treating this
population or no differences in retention rates for substance users with and without ASPD
co-morbidity (e.g. Gil, Nolimal, & Crowley, 1992; King et al., 2001; Marlowe, Kirby,
Festinger, Husband, & Platt, 1997). Therefore, it remains unclear the extent and
circumstance under which ASPD is a risk factor for poor substance use treatment outcomes.
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One variable that may be affecting treatment retention rates for ASPD patients is whether
the patient is receiving treatment voluntarily or through the court system. As one example,
individuals in pretrial release to treatment programs are offered the opportunity to avoid a
criminal record or incarceration contingent upon the successful completion of a substance
use treatment program (Young, Fluellen, & Belenko, 2004). Overall, empirical evidence
suggests that these programs are effective in retaining patients in treatment, reducing
substance use, and reducing rates of recidivism compared to criminal offenders not
mandated to court and those mandated to programs such as probation and drug court
(Harrell & Cavanaugh, 1995; Harrell, 1998; Young, 2002; Young & Belenko, 2002; Young,
Fluellen, & Belenko, 2004). For instance, patients in a pretrial program in Brooklyn, NY,
the Drug Treatment Alternative to Prison (DTAP) program, were compared to control
offenders and patients mandated to treatment through parole, probation, and drug court
programs. Findings indicated that the DTAP patients had higher rates of retention than the
other groups at both 6 and 12 month post-admission follow-ups (Young, 2002; Young &
Belenko, 2002). Further, a follow-up study examining the effectiveness of DTAP reported
that criminal recidivism among DTAP participants were substantially below those of a
matched comparison group of offenders who were mandated to treatment from conventional
criminal justice sources (Young, Fluellen, & Belenko, 2004). In considering the effects of
pretrial release to treatment programs on individuals with ASPD, one study examining
treatment outcome in a group of court-mandated substance users found that comorbid ASPD
was not associated with treatment dropout, and that this group fared equally well compared
to the court mandated non-ASPD patients in terms of reduced drug use and recidivism rates
(Messina, Wish, & Nemes, 1999), suggesting the feasibility of court mandated programs in
retaining substance abusing clients with ASPD in treatment.
Based on suggestive, yet mixed findings separately suggesting the potential relevance of
ASPD status and the role of the court system in understanding substance use treatment
dropout, further research considering the interaction of these variables may be useful.
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Specifically, given the knowledge that ASPD patients are at an increased risk for treatment
dropout, and that utilizing the court system to retain substance using patients appears
effective, it is important to understand whether the court system improves retention rates
specific to ASPD patients. Evidence from the Messina, Wish, and Nemes (1999) study
suggests that ASPD patients respond well to court-mandated treatment. However, a
voluntary-treatment comparison group was not included in the study. This omission is
important because it precludes comparison with ASPD drug users receiving treatment on a
voluntary basis, who may be at a heightened risk for treatment dropout in the absence of
treatments with clear contingencies for remaining in treatment (Brooner, Kidorf, King, &
Stoller, 1998; Messina, Farabee, & Rawson, 2003; Silverman et al., 1998). Thus, the current
study attempts to further address this issue by examining the interactive effects of courtmandated treatment and ASPD status on treatment dropout among 236 inner-city male
substance users receiving residential substance abuse treatment through a pretrial release to
treatment program.

2. Materials and Method
Participants

NIH-PA Author Manuscript

Participants for this study included 236 male residents of the Salvation Army Harbor Light
residential substance abuse treatment facility in Northeast Washington, DC. The mean age
of the sample was 40.5 years (SD = 9.8), 91.7% were African American, and 50.7% reported
earning an income of less than $20K per year. For the current sample, patients entered the
treatment center either voluntary or under a pretrial release to treatment program through the
District of Columbia Pretrial Services Agency. In this program, drug offenders who were
awaiting trial were granted pretrial supervision through the pretrial services offered through
the court system. Under this status, individuals were given the option to receive substance
abuse treatment as a way to ensure appearance in court, provide community safety, and
address the underlying cause of recidivism. The patients were aware that if they successfully
completed the program within a designated time frame they were given the opportunity to
have their sentences reduced or expunged. However, in cases where they voluntarily
withdrew from the program or were noncompliant with the terms of their release contract,
they would be subject to a variety of sanctions including contempt of court and detention or
revocation of their release.
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Patients were contracted to a specific length of stay upon entry into the treatment center. For
the current sample, contract lengths included 30 days (42.2%), 60 days (21.5%), 90 days
(11.0%) or 180 days (25.3%). Pretrial release to treatment patients were assigned contract
lengths based on an assessment of the patients' need from the Social Services and
Assessment Center of the D.C. Pretrial Services Agency. Although there are no clear criteria
for assignment to a specific contract length, the recommendation takes into consideration the
patients' drug use and criminal history. Voluntary patients are assigned contract lengths
based upon the availability of financial support from government and community agencies.
Treatment at Harbor Light consisted primarily of group sessions focused on a combination
of relapse prevention, AA/NA, chemical dependency, and functional analysis. While in
treatment, patients were required to abstain from all drug use, with the exception of nicotine,
as well as remain on the center grounds for the duration of their stay. Detoxification was
required prior to entrance into the treatment facility and regular drug testing was provided,
with positive tests serving as grounds for immediate dismissal from the center.
Procedure
Adult male residents were approached within their first week of treatment and were asked if
they would be interested in participating in a research study examining personality and
J Subst Abuse Treat. Author manuscript; available in PMC 2013 March 02.
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behavioral characteristics of substance users. Interested participants were given a more
detailed verbal description of the study and then provided written informed consent; all
aspects of the study and the consent forms were approved by the University of Maryland
Institutional Review Board.
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Following informed consent, participants completed the Antisocial Personality Disorder
Module of the Structured Clinical Interview for DSM-IV Personality Disorders (SCID-II;
First, Spitzer, Gibbon, Williams & Benjamin, 1997) and the Substance Dependence
Modules of the Structured Clinical Interview for DSM-IV Axis I Disorders (SCID-I; First,
Spitzer, Gibbon & Williams, 2002). Participants also completed self-report measures
including a demographics form, the Center for Epidemiological Studies-Depression scale
(CES-D; Radloff, 1977) to assess depressive affect and overall depressive symptomatology
in the week prior to testing, and polysubstance use. Polysubstance use was assessed using a
self report measure of frequency of substance use across the 10 drug categories in line with
the work of Kirisci, Vanyukov, Dunn, and Tarter (2002). Participants indicated their use for
each substance across the following categories: never, one time, monthly, 2-4 times a month,
2-3 times a week, or 4 or more times a week in the past year. Polysubstance use was defined
as using 3 or more substance on a weekly basis in the past year. We chose 3 substances
because (1) in the DSM-IV-TR polysubstance dependence requires an individual to use at
least three different substances in the same 12-month period to be given the diagnosis of
polysubstance dependence (APA, 1994), and (2) 88.3% of the sample reported using at least
2 substances on a weekly basis in the past year, thereby precluding an analysis of any
meaningful differences. Participants also provided additional information on their past
treatment history including how many previous substance abuse treatment attempts they had
made prior coming to Harbor Light.
The entire assessment lasted approximately 1 hour. Patients received $15 in cash for
participation in the study. This payment was deposited into their account at Harbor Light,
which they received upon discharge from the residential treatment center.
Analytic Plan
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Analyses were conducted with dropout as the primary dependent variable. Given the
multiple contract lengths, we decided to examine dropout by 30 days of treatment for three
reasons: 1) this was the minimum contract duration across all participants, 2) it is consistent
with our previous research on treatment dropout with multiple contract durations (e.g.,
Daughters et al., 2005); and 3) 30 day contracts are considerably more common here as well
as outside of this Center, thereby increasing the generalizability of the findings1. Because of
the skewed distribution in dropout at 30 days of treatment (13.1% dropped out of treatment),
this variable was coded categorically as dropout or completer across 30 days of treatment. In
addition to our primary analyses with the categorical variable of dropout, we also conducted
a discrete-time survival analysis to predict days until dropout during the first 30 days of
treatment using Cox proportional hazards regression to provide a richer analysis of dropout
that does not require normally distributed outcome data.
Primary analyses began with descriptives for the entire sample across the dependent variable
of dropout, the independent variables of ASPD and court-mandated (CM) status, and the
potential covariates which include demographics, contract length, depressive symptoms,
polysubstance use, treatment history, and substance dependence. Next, we examined
differences in the potential covariates across the dependent variable and then the

1We also conducted all analyses with ‘Overall Dropout’ as the dependent variable (if a patient dropped out at any time in their
contract) and our analyses remained unchanged.
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independent variables to determine their use as covariates in subsequent regression analyses.
The primary analyses began with a logistic regression to examine the categorical variable of
dropout, utilizing covariates, ASPD status and CM status in the first step, and the interaction
of ASPD and CM in the second step. Follow-up chi-square analyses were used to compare
dropout across each resulting group based on a significant interaction. Secondary analyses
used methodologies from survival analysis (e.g., Kaplan-Meier, Cox regression) to model
the time to 30-day dropout, with days as the time scale.

3. Results
Descriptives for the Entire Sample

NIH-PA Author Manuscript

In the final sample, 13.1% dropped out of treatment within 30 days (dropouts; n = 31) and
86.9% completed at least 30 days of treatment (completers, n = 205); 39.4% met criteria for
DSM-IV antisocial personality disorder (ASPD; n = 93); and 72.5% were court mandated to
treatment (CM; n = 171). Table 1 provides a comparison of 30-day treatment dropout and
overall treatment dropout (participants who dropped out at any time during treatment)
between CM and voluntary patients within each contract length. The mean score on the
CES-D for the entire sample was 22.3 (SD = 11.4). With regard to substance use, 58.4% of
the sample reported polysubstance use, 33.1% (n = 78) met criteria for alcohol dependence,
14.0% (n = 33) for marijuana dependence, 38.6% (n = 91) for heroin dependence, 58.1% (n
= 137) for cocaine dependence, 5.9% (n = 14) for hallucinogen dependence, and 27.2% (n =
63) of the sample met dependence for more than one substance.
Relationship among Covariates and Dropout Status
Analyses of the relationship comparing dropout status and potential covariates are provided
in Table 2. Significantly more dropouts than completers met criteria for marijuana
dependence, χ2(1) = 6.72, p < .01. There were no significant differences between dropouts
and completers on dependence on any other substance, polysubstance use, contract length,
age, income, or self-reported depressive symptoms (ps > .05).
Relationship among Covariates, ASPD, and Court Mandated Status
Differences in contract length comparing voluntary and court-mandated patients can be
found in Table 3. As there were no significant differences in contract length within ASPD
patients, the data for only the voluntary and court-mandated groups are presented in Table 3.
The CM patients were significantly more likely to have 30 day [χ2(1) = 35.8, p < .001] and
60-day [χ2(1) = 15.3, p < .001] contracts and the voluntary patients were more likely to
have 180 day contracts [χ2(1) = 97.3, p < .001].
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Considering ASPD and CM status together, the relationship between the four resulting
groups and the covariates are discussed below and presented in Table 4. Significantly more
of the Voluntary/No ASPD than CM/No ASPD patients met criteria for heroin dependence
[χ2(1) = 4.8, p < .05]. Voluntary/No ASPD patients were also significantly more likely than
CM/ASPD patients to be a polysubstance user [χ2(1) = 5.4, p < .05] and meet criteria for
heroin dependence [χ2(1) = 7.6, p < .01]. The Voluntary/ASPD patients were significantly
more likely than the CM/No ASPD patients to meet criteria for alcohol [χ2(1) = 9.6, p < .
01] and marijuana [χ2(1) = 7.6, p < .01] dependence. Finally, the Voluntary/ASPD patients
were significantly more likely than the CM/ASPD patients to report a lower income [χ2(1)
= 4.3, p < .05] and meet criteria for alcohol dependence [χ2(1) = 5.0, p < .05]. There were
no group differences in cocaine dependence, hallucinogen dependence, age, or self-reported
depressive symptoms.
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A logistic regression analysis was conducted to determine the unique and interactive effects
of ASPD and CM status on 30-day treatment dropout. As indicated in Table 5, CM status
and ASPD were included in the first step, along with variables that demonstrated a
significant group difference, namely contract duration, income, alcohol dependence, heroin
dependence, marijuana dependence, and polysubstance use. In the first step there was a main
effect for CM status, indicating that individuals who were court-mandated to treatment were
significantly more likely to drop out of treatment than those who were not court-mandated
(Wald = 7.41, p < .01; OR = 0.21; 95% CI = 0.07 –0.65). The ASPD/CM status interaction
variable was entered in a second step, and the final model was significant, χ2 = 26.2, p < .
001, with the ASPD/CM status interaction significantly related to treatment dropout, (Wald
= 8.48, p < .01, OR = 0.04, 95% CI = 0.01 – 0.36). Follow-up chi square analyses indicated
that Voluntary/ASPD patients were significantly more likely to drop out of treatment than
Voluntary/non ASPD (χ2(1) = 4.4, p < .05), Court Mandated/ASPD (χ2(1) = 4.1, p < .001),
and CM/non ASPD (χ2(1) = 10.1, p < .001) patients. There were no differences in rates of
treatment dropout across Voluntary/non ASPD, CM/ASPD, and CM/non ASPD patients.
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As a richer analysis of dropout, we also conducted a discrete-time survival analysis to
predict days until dropout during the first 30 days of treatment using Cox proportional
hazards regression. Court-mandated status and ASPD were included in the first step, along
with variables that demonstrated a significant group difference, namely contract duration,
income, alcohol dependence, heroin dependence, marijuana dependence, and polysubstance
use. The ASPD/CM status interaction variable was entered in a second step, and the final
model was significant, χ2 (9, N = 236) = 36.2, p < .001, with the ASPD/CM status
interaction significantly related to treatment dropout, B = −3.17, SE = 1.11, hazard ratio = .
04, p < .01. We ran an additional Cox proportional hazards regression with the same
variables but included all four groups, contrasting ASPD/voluntary status to the other 3
groups. As displayed in Figure 1, ASPD patients who enter treatment voluntarily were at an
increased risk for dropping out of treatment compared to the other three groups.

4. Discussion
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The current study examined the interactive effect of ASPD and court-mandated status on
treatment dropout among substance users receiving residential treatment. Consistent with
prior research (Glass & Marlowe, 1994; Martin et al., 2003; Schnoll, Goldstein, Antes, &
Rinella, 1980), evidence indicated that court-mandated substance users were significantly
more likely to remain in treatment compared to those voluntarily receiving treatment.
Although there was no significant differences in treatment dropout between the ASPD and
non-ASPD substance users, an interaction was evident such that dropout was more likely
among ASPD patients voluntarily receiving treatment than ASPD patients who were courtmandated to treatment, suggesting that patients with comorbid ASPD and substance
dependence who are not court-mandated to treatment are at an increased risk of dropping out
of residential substance use treatment. The implications of these findings are twofold. First,
the data support the utility of pretrial release to treatment programs in retaining ASPD
substance users in the criminal justice system. Second, these findings suggest value in
developing specialized interventions to be combined with standard treatment that meet the
specific needs of ASPD substance users who enter treatment voluntarily to prevent
premature treatment dropout.
Given these findings, an important question to answer is why ASPD and voluntary treatment
entry indicates such a substantial vulnerability to treatment dropout. To this end, key
characteristics of individuals with ASPD include the engagement in impulsive and chaotic
behaviors and an inability to inhibit emotional responses, tolerate frustration and boredom,
J Subst Abuse Treat. Author manuscript; available in PMC 2013 March 02.
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and problem solve (DSM-IV; APA, 1994). These vulnerabilities may place ASPD patients
at a disadvantage in treatment such that abstinence is associated with withdrawal symptoms
and social and environmental changes which often lead to increases in negative affective
states such as frustration and irritability. Indeed, data suggests that ASPD substance users
exhibit significantly lower levels of distress tolerance, or persistence in goal directed activity
during times of emotional distress, than substance users without ASPD (Daughters,
Sargeant, Bornovalova, Gratz, & Lejuez, under review), and evidence indicates that low
distress tolerance is significantly related to treatment dropout (Daughters et al., 2005). Thus,
assessing this vulnerability in the beginning of treatment and subsequently providing
appropriate interventions (i.e., distress tolerance skills) may serve to decrease rates of
treatment dropout for this at-risk group.
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An additional question resulting from these results is why court-mandated treatment
facilitates treatment retention among individuals with ASPD. Current evidence suggests that
substance users with ASPD respond particularly well to treatment programs that offer
reinforcement contingencies (Brooner et al., 1998; Messina, Farabee, & Rawson, 2003;
Silverman et al., 1998). For example, Messina and colleagues (2003) randomly assigned a
group of methadone maintained cocaine users with and without ASPD to one of four
treatment conditions including cognitive-behavioral therapy (CBT), contingency
management (CM), cognitive-behavioral therapy plus contingency management (CBT +
CM), or methadone maintenance (MM). ASPD patients in the CM condition were
significantly more likely to abstain from cocaine use than those in the CBT-only condition.
Furthermore, ASPD patients in the CM condition were significantly more likely to abstain
from cocaine use than non-ASPD patients in the CM condition, even after controlling for
pre-existing differences, highlighting the specificity of the effects of CM interventions on
individuals with ASPD. These results are consistent with the hypothesis that although
individuals with ASPD may not be intrinsically motivated for substance use rehabilitation
they are likely to comply when concurrently receiving a personal benefit or gain (Evans &
Sullivan, 1990; Valliant, 1975), even in the case of court-mandated treatment where the
reinforcement contingencies are better characterized as negative reinforcement (avoidance
of sever legal consequences) as opposed to positive reinforcement.

NIH-PA Author Manuscript

A number of limitations need to be considered when interpreting these results. First, our
participants were mandated to treatment through a pretrial release to treatment program.
There are a variety of additional court mandated programs, including drug court and
probation, which need empirical attention prior to generalizing our findings to these groups.
Second, this sample was limited to individuals receiving residential substance use treatment.
Future studies need to determine if these results generalize across other types of treatment
settings (e.g., outpatient). Third, other potential predictors of substance use treatment
dropout such as social support, treatment readiness, self efficacy, and Axis-I comorbidity
were not assessed. A more comprehensive assessment of psychopathology and other
relevant drop-out predictors is warranted. For example, in addition to more standardized
measures of treatment readiness or motivation, it will be important to assess factors that may
influence ones feeling of commitment or obligation to treatment (i.e., social/family
pressure). Fourth, the sample does not include women and primarily consists of low-income
inner-city African Americans. Therefore, it is unclear if these findings would extend to
females and individuals of other ethnicities and socioeconomic status. Finally, we did not
conduct a comprehensive assessment of legal and criminal history, which evidence indicates
may affect treatment retention (Nielson & Scarpitti, 2002), highlighting the importance of
including this variable in future studies.
In summary, the high prevalence rate of comorbid ASPD and substance dependence along
with the large public health costs associated with this dual diagnosis has lead researchers to
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examine the ability of standard substance use interventions to effectively treat this
population. Given the importance of treatment retention in long term substance use
outcomes, the current study examined the interactive effect of ASPD and court-mandated
status in predicting treatment dropout among a group of inner-city male substance users in a
residential drug treatment facility. Along with highlighting the effectiveness of courtmandated treatment efforts in retaining ASPD substance users, these results suggest that
substance dependent individuals with ASPD who are voluntarily in treatment are at an
increased risk for treatment dropout compared to all other groups. Although the implications
must be tempered by the limitations outlined above, this current paper sets the stage for
future work to replicate these findings and extend them to consider exactly “why”
individuals with ASPD are more likely to drop out of treatment when a legal obligation is
not present and how to best address these vulnerabilities in treatment. The public health
relevance of such knowledge would be further increased by the opportunity to develop
specialized interventions aimed at these specific vulnerabilities and to implement these
interventions in the early stages of substance use treatment with the goal of improving
adherence for this at-risk group.
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Figure 1.

Group differences in cumulative survival to dropout (Y-axis) over the first 30 days of
treatment among antisocial personality disorder (ASPD) and non-ASPD patients who are
either court mandated (CM) to treatment or enter treatment voluntarily.
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Differences between dropouts and completers on demographics, substance dependence, and self report
measures.
Dropouts (n = 31)

Completers (n = 205)

38.8 (SD = 9.7)

41.2 (SD = 9.7)

62.1%

50.0%

# of Previous Treatments

2.69 (SD = 3.50)

2.12 (SD = 1.82)

Depressive Symptoms

22.7 (SD = 11.7)

22.2 (SD = 11.4)

Alcohol Dependence

44.8%

31.4%

Cocaine Dependence

62.1%

57.5%

Heroin Dependence

24.1%

40.6%

Marijuana Dependence*

27.6%

12.1%

Hallucinogen Dependence

10.3%

5.3%

Polysubstance Use

59.3%

64.2%

Age
Income (> 20k)

*

p < .01
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Table 3

Differences in contract length between voluntary and court mandated participants.
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Contract Length

Voluntary (n = 65)

Court Mandated (n = 171)

30-Day***

10.8%

53.8%

60-Day***

4.6%

28.1%

90-Day

13.8%

9.9%

180-Day***

70.8%

7.3%

***

p < .001
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Table 4

NIH-PA Author Manuscript

Group differences between antisocial personality disorder (ASPD) and court mandated (CM) participants on
demographics, substance dependence, and self report measures.
Voluntary Treatment Entry

Court Mandated Treatment Entry

NIH-PA Author Manuscript

No ASPD
(n = 35)

ASPD
(n = 30)

No ASPD
(n = 62)

ASPD
(n = 109)

42.9 (SD = 8.7)

39.4 (SD = 8.0)

40.6 (SD = 10.4)

40.9 (SD = 9.8)

51.4%a,b

63.3%a

54.1%a,b

40.3%b

# of Previous Treatments

2.97 (SD = 3.5)

1.86 (SD = 1.46)

2.10 (SD = 1.80)

2.22 (SD = 2.11)

Depressive Symptoms

23.3 (SD = 12.9)

24.9 (SD = 13.0)

22.7 (SD = 10.7)

22.3 (SD = 11.4)

Alcohol Dependence

34.3%

56.7%a

26.6% b

32.3% b

Cocaine Dependence

62.8%

56.7%

56.0%

59.7%

Heroin Dependence

20.0% a

33.3%

40.3% b

48.4% b

Marijuana Dependence

11.4%

30.0% a

10.1% b

14.5%

Hallucinogen Dependence

5.7%

3.3%

6.4%

6.5%

50.0% a

70.0%

61.0%

73.8% b

Age
Income (< 20k)

Polysubstance Use

*

Differing subscripts indicate a significant group difference
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-0.01
0.14
-1.56

Polysubstance Use

ASPD

CM Status**

CM × ASPD **

Indicates p < .01

**

Indicates p < .05,

*

-0.47

Heroin Dependence

-3.17

0.66

Final Model**

0.52

Marijuana Dependence

0.16

Alcohol Dependence

-0.01

Income

B

Contract Length

Initial Model*

Predictor

1.09

0.57

0.45

0.45

0.50

0.55

0.44

0.42

0.00

SE (B)

8.48

26.2

7.41

0.10

0.00

0.89

1.46

1.39

0.15

2.28

15.66

Wald χ2

0.04

0.21

1.15

0.99

0.63

1.94

1.69

1.18

0.99

OR

0.01 – 0.36

0.07 – 0.65

0.48 – 2.77

0.41 – 2.42

0.24 – 1.66

0.66 – 5.67

0.71 – 4.03

0.52 – 2.68

0.99 – 1.00

95% CI

Logistic regression analysis of the interactive effects of ASPD and CM status on treatment dropout.
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